The Malta experience. Isoprodian-rifampicin combination treatment for leprosy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003622:Dapsone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007539:Isonicotinic Acids / Q000008:administration & dosage*; D007917:Leprostatic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011515:Prothionamide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D004338:Drug Combinations; D007539:Isonicotinic Acids; D007917:Leprostatic Agents; C011004:isoprodian; D011515:Prothionamide; D003622:Dapsone; D007538:Isoniazid; D012293:Rifampin